eligibility_summary
Eligible: histologically confirmed relapsed/refractory large B-cell lymphoma at last relapse, after ≥2 prior chemotherapy lines, ECOG 0–1, no significant donor-specific anti-HLA antibodies, adequate hematologic, renal, and hepatic function. Exclude: active CNS malignancy, autologous or allogeneic HSCT within 6 months before lymphodepletion, hypocellular bone marrow for age.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT05714345: Randomized, open-label phase 2 trial in relapsed/refractory large B-cell lymphoma testing lymphodepletion with ALLO-647 + fludarabine + cyclophosphamide versus fludarabine + cyclophosphamide alone, followed by ALLO-501A infusion. Interventions/mechanisms: ALLO-501A (genetic, allogeneic anti-CD19 CAR T-cell therapy) redirects T cells to CD19 to kill malignant B cells, ALLO-647 (biologic, anti-CD52 monoclonal antibody) depletes CD52+ host lymphocytes to enhance CAR T engraftment/persistence, fludarabine (drug, purine analog chemotherapy) inhibits DNA synthesis for lymphodepletion, cyclophosphamide (drug, alkylating chemotherapy) crosslinks DNA for lymphodepletion. Targets: CD19 on B-cell lymphoma, CD52 on host lymphocytes, global lymphocyte depletion pathways to facilitate CAR T activity.